NOV 28, 2016 11:07 AM PST

Cancer Drug May be Repurposed to Treat Muscular Dystrophy

WRITTEN BY: Xuan Pham
A cancer drug that’s approved for the treatment of kidney cancer may also be effective against a form of muscular dystrophy.
 

Sunitinib is a small-molecule drug that inhibits receptor tyrosine kinases (RTK). It was approved by the FDA for the treatment of renal cell carcinoma and a form of gastrointestinal tumor in 2006. Now, researchers at the King’s College London say the mechanism behind this drug may also act to improve muscle strength in patients with facioscapulohumeral dystrophy (FSHD).
 
FSHD is a genetically inherited form of muscular dystrophy that primarily affects the muscles around the face, shoulders, and upper arms. Patients with this condition experience progressive muscle wasting that starts in early childhood. The muscle weakness can severely impair mobility, speaking, and even breathing.
 
"Muscle dystrophies are an untreatable collection of diseases that result in progressive loss of mobility and often premature death, and affect millions of people worldwide,” said Robert Knight, Principal Investigator at the Division of Craniofacial Development and Stem Cell Biology at King’s College London’s Dental Institute, and the study’s co-lead author.
 
In studying muscle biology, researchers noted that a receptor tyrosine kinase Rearranged during transfection (RET) seemed to be upregulated in muscle stem cells that express the DUX4 protein. In FSHD, the genomic region controlling DUX4 appears to be abnormally activated (due to hypomethylation). This, in turn, overstimulates the production and activity of DUX4, which seems to contribute to the muscle weakness characteristic of FSHD.
 
Could an RTK inhibitor reverse this effect? This was the researcher’s main hypothesis, and they tested it first by confirming that overexpression of DUX4 in mice led to upregulation of RET. Furthermore, administration of sunitinib, an RTK inhibitor, suppressed RET activity and reduced damage to muscle cells.
 

“Specifically, blocking DUX4-mediated RET signaling increases myogenic differentiation, giving further insight into the molecular pathology of DUX4 and highlighting RET signaling as potential drug target," the authors explain.
 
The drug shows promise in improving muscle strength for patients afflicted with FSHD. And since the drug is already approved, repurposing it for the treatment of FSHD may take much less time, assuming further studies also find the same promising results.
 
“The discovery that an approved anticancer treatment may prove useful for enhancing the ability of stem cells to repair muscle in a type of muscle dystrophy affecting face and shoulder muscles offers a new route for putative therapies for many patients,” said Knight.

Additional sources: King's College London press release, MNT
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 16, 2019
Cancer
OCT 16, 2019
The price of cancer
Are you ready for some big, scary numbers? In 2015, 492,146 people between the ages of 16 and 84 died from cancer in the United States. That is equivalent ...
OCT 16, 2019
Cancer
OCT 16, 2019
New anticancer agent discovered
A new study published in the Journal of the American Chemical Society showcases research from Purdue University on the development of an anticancer agent t...
OCT 16, 2019
Cancer
OCT 16, 2019
Combining Breast and Lung Cancer Drugs to Overcome Treatment Resistance
The efforts to overcome cancer’s ability to evolve and resist treatment take many forms and comprise a vital and active branch of contemporary cancer...
OCT 16, 2019
Cancer
OCT 16, 2019
Urine test detects cancer: watch out for blue pee!
New research from MIT engineers and Imperial and published in Nature Nanotechnology could change the way to detect cancer. The study highlights the develop...
OCT 16, 2019
Cancer
OCT 16, 2019
Cancer drugs don't work the way we thought
New research recently published in the journal Science Translational Medicine surprises the oncological community with findings that a protein previously t...
OCT 16, 2019
Cancer
OCT 16, 2019
Don't eat iron-rich foods with your tomatoes
We have known for some time now that tomatoes are beneficial for our health. The carotenoid called lycopene in tomatoes contains high amounts of antioxidan...
Loading Comments...